Skip to main content
. 2020 Sep 15;5(1):111–118. doi: 10.1002/ags3.12399

Table 1.

Comparison of demographics between patients with and without right‐half dissection of SMA nerve plexus

Dissection (n = 37) Preservation (n = 37) P
Clinical variables
Age, years 64.8 ± 8.9 65.3 ± 9.1 0.8028
Sex, male/female 24 (64.9%) /13 (35.1%) 23 (62.2%)/ 14 (37.8%) 1.0000
Performance status, 0/1 36 (97.3%)/ 1 (2.7%) 36 (97.3%)/ 1 (2.7%) 1.0000
Body mass index, kg/m2 21.1 ± 2.8 21.4 ± 2.4 0.5954
NCCN resectability status
R 29 (78.4%) 30 (81.1%) 0.7105
BR‐PV 7 (18.9%) 5 (13.5%)
BR‐A 1 (2.7%) 2 (5.4%)
Tumor size, mm 23.0 ± 7.2 23.8 ± 8.1 0.6513
Biliary drainage 17 (46.0%) 23 (62.2%) 0.2433
Neoadjuvant therapy 16 (43.2%) 12 (32.4%) 0.4725
Preoperative radiation therapy 2 (5.4%) 4 (10.8%) 0.6741
CEA, ng/ml 27.6 ± 126.0 5.2 ± 5.8 0.2865
CA19‐9, U/ml 320.5 ± 827.5 765.2 ± 1713.9 0.1612
DUPAN‐2, U/ml 305.0 ± 415.8 282.8 ± 600.3 0.8756
Operation time, min 450.3 ± 111.7 491.4 ± 108.8 0.1134
Blood loss, ml 892.4 ± 565.8 1024.7 ± 649.1 0.3530
Portal vein resection 16 (43.2%) 21 (56.8%) 0.3525
Blood transfusion 5 (13.5%) 5 (13.5%) 1.0000
Pathological invasion of SMA nerve plexus 2 (5.4%) 3 (8.1%) 1.0000
Residual tumor, R0/R1 35 (94.6%)/ 2 (5.4%)` 31 (83.8%)/ 6 (16.2%) 0.2611
SMA margin 0 (0.0%) 1 (2.7%)
Dissected pancreatic margin 2 (5.4%) 5 (13.5%)
UICC stage (7th edition)
IA 3 (8.1%) 3 (8.1%) 0.9188
IB 1 (2.7%) 0 (0.0%)
IIA 9 (24.3%) 7 (18.9%)
IIB 21 (56.8%) 24 (64.9%)
III 1 (2.7%) 1 (2.7%)
IV 2 (5.4%) 2 (5.4%)

Data are expressed as mean ± standard deviation or n (%).

Abbreviations: BR‐A, borderline resectable with arterial invasion; BR‐PV, borderline resectable with portal vein invasion; CA19‐9, cancer antigen 19‐9; CEA, carcinoembryonic antigen; R, resectable; SMA, superior mesenteric artery; UICC, Union for International Cancer Control.